CURRENT MANAGEMENT OF GOUT

被引：0

作者：

Miguel, Claudia ^{[1
]}

Mediavilla, Maria Jesus ^{[1
]}

机构：

[1] Inst Portugues Reumatol, Lisbon, Portugal

来源：

ACTA MEDICA PORTUGUESA | 2011年 / 24卷 / 05期

关键词：

URIC-ACID; CARDIOVASCULAR-DISEASE; XANTHINE-OXIDASE; HYPERURICEMIA; ALLOPURINOL; FEBUXOSTAT; ARTHRITIS; INHIBITOR; TRIAL; INDOMETHACIN;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CURRENT MANAGEMENT OF GOUT Gout, one of the most prevalent rheumatic diseases in the world, results from deposition of uric acid crystals in several locations, particularly in joints, subcutaneous tissues and kidney. The classical treatments, although effective, are often poorly tolerated or contraindicated. Recently, new drugs have emerged for the treatment of hyperuricemia and gout, including febuxostat and uricase, which proved to be quite promising. Some drugs already used in other diseases, such as losartan, atorvastatin, fenofibrate and amlodipine also seem to have a role in monitoring the serum uric acid. This article reviews the pathophysiology, clinical management and current therapeutic options for Hyperuricemia and Gout.

引用

页码：791 / 798

页数：8

共 35 条

[1] DOES COLCHICINE WORK - THE RESULTS OF THE 1ST CONTROLLED-STUDY IN ACUTE GOUT
AHERN, MJ
REID, C
GORDON, TP
MCCREDIE, M
BROOKS, PM
JONES, M
[J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1987, 17 (03): : 301 - 304
[2] ALLOWAY JA, 1993, J RHEUMATOL, V20, P111
[3] ALTMAN A, 2001, SEMIN ONCOL S5, V28, P623
[4] Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
Baker, JF
Krishnan, E
Chen, L
Schumacher, HR
[J]. AMERICAN JOURNAL OF MEDICINE, 2005, 118 (08) : 816 - 826
[5] Current management of gout in patients unresponsive or allergic to allopurinol
Bardin, T
[J]. JOINT BONE SPINE, 2004, 71 (06) : 481 - 485
[6] Febuxostat compared with allopurinol in patients with hyperuricemia and gout
Becker, MA
Schumacher, HR
Wortmann, RL
MacDonald, PA
Eustace, D
Palo, WA
Streit, J
Joseph-Ridge, N
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2450 - 2461
[7] Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski J.S.
Clark M.A.
[J]. Current Rheumatology Reports, 2004, 6 (3) : 240 - 247
[8] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
Bruce, Susan P.
[J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
[9] Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients
Chanard, J
Toupance, O
Lavaud, S
de Ligny, BH
Bernaud, C
Moulin, B
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2147 - 2153
[10] Gout: can we create an evidence-based systematic approach to diagnosis and management?
Chen, Lan X.
Schumacher, H. Ralph
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (04): : 673 - 684

← 1 2 3 4 →